Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shuang Liang, Yan-Jun Liang, Zhao Li, Yong Wang, Xin-Ru Guo, Chao-yang Zhang, Chun Zhang, Jie Wu, Xiao-Long Wang, Yi-Sha Li, Guang-Yan Cai & Xiang-Mei Chen. (2023) Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients. Therapeutics and Clinical Risk Management 19, pages 351-360.
Read now
Read now
Yaling Guo, Xueping Wu, Lei Liu, Haifeng Zhang, Lijuan Yang & Weidong Chen. (2020) Efficacy of leflunomide combined with prednisone for the treatment of PLA2R-associated primary membranous nephropathy. Renal Failure 42:1, pages 122-130.
Read now
Read now
Articles from other publishers (20)
Zhirong Fan, Lin Lei, Shengyao Su, Shu Zhang, Nairong Xie, Ling Li, Yan Lu, Li Di, Min Wang, Min Xu, Xin‐Ming Shen & Yuwei Da. (2023) Comparison between mono‐tacrolimus and mono‐glucocorticoid in the treatment of myasthenia gravis. Annals of Clinical and Translational Neurology 10:4, pages 589-598.
Crossref
Crossref
Neng Bao, Mingjia Gu, Xiang Yu, Jin Wang, Leiping Gao, Zhiwei Miao & Wei Kong. (2023) Immunosuppressive treatment for idiopathic membranous nephropathy: An updated network meta-analysis. Open Life Sciences 18:1.
Crossref
Crossref
Weijia Yuan, Lin Sui, Haili Xin, Minchao Liu & Huayu Shi. (2022) Discussion on machine learning technology to predict tacrolimus blood concentration in patients with nephrotic syndrome and membranous nephropathy in real-world settings. BMC Medical Informatics and Decision Making 22:1.
Crossref
Crossref
Miaomiao Chen, Xuehan Zhang, Yi Xiong & Gaosi Xu. (2022) Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis. International Urology and Nephrology 55:3, pages 641-651.
Crossref
Crossref
Jiarong Liu, Xiang Li, Tianlun Huang & Gaosi Xu. (2022) Efficacy and safety of 12 immunosuppressive agents for idiopathic membranous nephropathy in adults: A pairwise and network meta-analysis. Frontiers in Pharmacology 13.
Crossref
Crossref
Miaomiao Chen, Jiarong Liu, Yi Xiong & Gaosi Xu. (2022) Treatment of Idiopathic Membranous Nephropathy for Moderate or Severe Proteinuria: A Systematic Review and Network Meta-Analysis. International Journal of Clinical Practice 2022, pages 1-12.
Crossref
Crossref
Francesco Scolari, Federico Alberici, Federica Mescia, Elisa Delbarba, Hernando Trujillo, Manuel Praga & Claudio Ponticelli. (2022) Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia. Frontiers in Immunology 13.
Crossref
Crossref
Jorge Rojas-Rivera, Fernando C. Fervenza & Alberto Ortiz. (2021) Recent Clinical Trials Insights into the Treatment of Primary Membranous Nephropathy. Drugs 82:2, pages 109-132.
Crossref
Crossref
Wei Lv, Mei-Rong Wang, Cheng-Zhen Zhang, Xue-Xu Sun, Zhen-Zhen Yan, Xiao-Min Hu & Tao-Tao Wang. (2021) Effect of Nephritis Rehabilitation Tablets combined with tacrolimus in treatment of idiopathic membranous nephropathy. World Journal of Clinical Cases 9:34, pages 10464-10471.
Crossref
Crossref
Thilo C von Groote, Gabrielle Williams, Eric H Au, Yizhi Chen, Anna T Mathew, Elisabeth M Hodson & David J Tunnicliffe. (2021) Immunosuppressive treatment for primary membranous nephropathy in adults with nephrotic syndrome. Cochrane Database of Systematic Reviews 2021:11.
Crossref
Crossref
Brad H. Rovin, Sharon G. Adler, Jonathan Barratt, Frank Bridoux, Kelly A. Burdge, Tak Mao Chan, H. Terence Cook, Fernando C. Fervenza, Keisha L. Gibson, Richard J. Glassock, David R.W. Jayne, Vivekanand Jha, Adrian Liew, Zhi-Hong Liu, Juan Manuel Mejía-Vilet, Carla M. Nester, Jai Radhakrishnan, Elizabeth M. Rave, Heather N. Reich, Pierre Ronco, Jan-Stephan F. Sanders, Sanjeev Sethi, Yusuke Suzuki, Sydney C.W. Tang, Vladimir Tesar, Marina Vivarelli, Jack F.M. Wetzels & Jürgen Floege. (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International 100:4, pages S1-S276.
Crossref
Crossref
Ruixia Ma, Ying Wang, Yan Xu, Rui Wang, Xianghua Wang, Ning Yu, Minghui Li & Yan Zhou. (2021) Tacrolimus Protects Podocytes from Apoptosis via Downregulation of TRPC6 in Diabetic Nephropathy. Journal of Diabetes Research 2021, pages 1-11.
Crossref
Crossref
Pinyuan Dai, Weihua Xie, Xiaojin Yu, Jinfang Sun, Shiyuan Wang & Joseph Kawuki. (2021) Efficacy and cost of different treatment in patients with idiopathic membranous nephropathy: A network meta-analysis and cost-effectiveness analysis. International Immunopharmacology 94, pages 107376.
Crossref
Crossref
Lifeng Gong, Min Xu, Wei Xu, Weigang Tang, Jingkui Lu, Wei Jiang, Fengyan Xie, Liping Ding & Xiaoli Qian. (2021) Efficacy and safety of tacrolimus monotherapy versus tacrolimus-corticosteroid combination therapy for idiopathic membranous nephropathy. Medicine 100:51, pages e28225.
Crossref
Crossref
Lifeng Gong, Min Xu, Wei Xu, Weigang Tang, Jingkui Lu, Wei Jiang, Fengyan Xie, Liping Ding & Xiaoli Qian. (2021) Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide–corticosteroid combination therapy for idiopathic membranous nephropathy. Medicine 100:28, pages e26628.
Crossref
Crossref
Shasha Chen, Song Ren, Amanda Y. Wang, Hieu Tran, Zheng Li, Xiaoyun Cheng, Manli Liu, Guisen Li, Li Wang & Daqing Hong. (2020) Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study. Trials 21:1.
Crossref
Crossref
Xiao‐Juan Zhang, Cheng‐Fa Ji, Jiang‐Zi Yuan, Lei Wang, Jing Zhang, Wei Fang, Dong‐Fang Bai & Zhao Hu. (2019) Efficacy and safety of tacrolimus‐based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study. The Kaohsiung Journal of Medical Sciences 35:10, pages 633-639.
Crossref
Crossref
Qiyan Zheng, Huisheng Yang, Weijing Liu, Weiwei Sun, Qing Zhao, Xiaoxiao Zhang, Huanan Jin & Luying Sun. (2019) Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. BMJ Open 9:9, pages e030919.
Crossref
Crossref
Yuan Yang, Li Zhao, Li Xiao, Yumei Liang, Chang Wang, Xiao Fu, Xuejing Zhu, Shuguang Yuan, Jianling Zhu, Xiaoping Zhu, Yinghong Liu, Jun Li, Jian Luo, Fuyou Liu & Lin Sun. (2018) Chlormethine Hydrochloride is Not Inferior to Tacrolimus in Treating Steroid-Resistant Nephrotic Syndrome. Kidney and Blood Pressure Research 43:1, pages 68-79.
Crossref
Crossref
Marley L. Watson, Bridgette K. Schroader & Heather D. Nelkin. 2018. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
489
505
.